Patient characteristics (n=20)
| Auto-PBSCT (n=12) | Thalidomide (n=8) | |
|---|---|---|
| Clinical profiles | ||
| Age (years) | 48 (36–61) | 69 (59–84) |
| Gender (male:female) | 9:3 | 5:3 |
| Time from symptoms to therapy (months) | 17 (2–120) | 25 (4–101) |
| Performance status | 1 (1–4) | 2 (1–3) |
| Overall Neuropathy Limitation Scale | 5 (1–11) | 6 (2–9) |
| Laboratory data | ||
| Albumin (g/dL) | 3.8 (2.7–4.5) | 3.4 (2.7–3.9) |
| Creatinine (mg/dL) | 0.7 (0.5–1.2) | 0.9 (0.4–2.0) |
| Immunoglobulin (IgA:IgG) | 4:6 | 2:5 |
| Vascular endothelial growth factor | 2950 (126–7870) | 2520 (1430–7970) |
| Nerve conduction study (median nerve) | ||
| CMAP amplitude (mV) | 5.3 (0–12.8) | 5.2 (0.1–9.4) |
| Motor conduction velocity (m/s) | 33.0 (23–45) | 26 (14–48) |
Data are given as median (range).
CMAP, compound muscle action potential; PBSCT, peripheral blood stem cell transplantation.